BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23287364)

  • 1. Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response.
    Jónsdóttir T; Zickert A; Sundelin B; Henriksson EW; van Vollenhoven RF; Gunnarsson I
    Rheumatology (Oxford); 2013 May; 52(5):847-55. PubMed ID: 23287364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term follow-up of patients with refractory systemic lupus erythematosus during rituximab treatment].
    Tsanian MÉ; Solov'ev SK; Torgashina AV; Aleksandrova EN; Radenska-Lopovok SG; Nikolaeva EV; Khrennikova IaB; Nasonov EL
    Ter Arkh; 2014; 86(5):40-9. PubMed ID: 25026801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
    Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
    Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of various cyclophosphamide treatment regimens on the course and outcome of lupus nephritis ].
    Petrović R; Stojanović R; Novicić-Sasić D; Dimitrijević J; Pavlović S; Stojković D; Palić-Obradović D; Stevanović G; Prodanović S
    Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():19-25. PubMed ID: 12583309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy.
    Camous L; Melander C; Vallet M; Squalli T; Knebelmann B; Noël LH; Fakhouri F
    Am J Kidney Dis; 2008 Aug; 52(2):346-52. PubMed ID: 18572292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis.
    Demircin G; Oner A; Erdoğan O; Delibaş A; Baysun S; Bülbül M; Bek K; Oksal A
    Ren Fail; 2008; 30(6):603-9. PubMed ID: 18661410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.
    Tanaka H; Oki E; Tsuruga K; Yashiro T; Hanada I; Ito E
    Clin Nephrol; 2009 Dec; 72(6):430-6. PubMed ID: 19954719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen.
    Ezeonyeji AN; Isenberg DA
    Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis.
    Conlon PJ; Fischer CA; Levesque MC; Smith SR; St Clair EW; Allen NB; Fleming JA; Howell DN
    Clin Nephrol; 1996 Sep; 46(3):170-5. PubMed ID: 8879851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.
    Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
    Ann Rheum Dis; 2007 Sep; 66(9):1259-62. PubMed ID: 17412738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients.
    Lu TY; Ng KP; Cambridge G; Leandro MJ; Edwards JC; Ehrenstein M; Isenberg DA
    Arthritis Rheum; 2009 Apr; 61(4):482-7. PubMed ID: 19333973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka.
    Herath N; Ratnatunga N; Weerakoon K; Wazil A; Nanayakkara N
    BMC Res Notes; 2017 Feb; 10(1):80. PubMed ID: 28148285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
    Gunnarsson I; Sundelin B; Jónsdóttir T; Jacobson SH; Henriksson EW; van Vollenhoven RF
    Arthritis Rheum; 2007 Apr; 56(4):1263-72. PubMed ID: 17393458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.
    Kim YG; Kim HW; Cho YM; Oh JS; Nah SS; Lee CK; Yoo B
    Rheumatology (Oxford); 2008 Mar; 47(3):311-4. PubMed ID: 18204087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
    Fischer-Betz R; Chehab G; Sander O; Vordenbäumen S; Voiculescu A; Brinks R; Schneider M
    J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
    Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
    Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study.
    Valeri A; Radhakrishnan J; Estes D; D'Agati V; Kopelman R; Pernis A; Flis R; Pirani C; Appel GB
    Clin Nephrol; 1994 Aug; 42(2):71-8. PubMed ID: 7955581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.